Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Cost of Sales Non-GAAP Adjustments by Year
Cost of Sales Non-GAAP Adjustments (Intangible Amortization & Restructuring) ($M) ($M)
Merck Cost of Sales Non-GAAP Adjustments: $4,355M in FY2025, up 50.0% from a year earlier.
Latest, FY2025
4,355
Period ended Dec 31, 2025
Change on a year earlier
+50.0%
2,904 in FY2024
History
5 years
Since FY2020
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| Cost of sales | $ | 16,382 | 2,871 | 1,484 | 4,355 | $ | 12,027”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 2a.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cost of Sales Non-GAAP Adjustments (Intangible Amortization & Restructuring) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4,355 | +50.0% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 2,904 | +30.3% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 2,229 | -1.5% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 2,264 | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2020 | Dec 31, 2020 | 3,790 | – | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
Cite this data
StockData. (2026). Merck Cost of Sales Non-GAAP Adjustments ($M), annual FY2020–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/nongaap-adj-cos
See every metric in the Merck KPI table. Data updated Oct 26, 2026.